Novavax, Inc. has seen the impact that a deal with big pharma can have on shareholder sentiment with activist investor Shah Capital ending its call for a leadership shake-up at the US vaccines maker, at least for the time being.
The hedge fund, which owns around 7.9% of Novavax’s common stock, has halted its campaign against the re-election of three Novavax directors
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?